Biotech Startups

ZModal builds infrastructure and software for real-time, model-driven biomanufacturing processes. The company serves biotech and pharmaceutical manufacturers seeking to optimize regulated production of biologics and living tissues.

1 investor

ZOLGENSMA is a gene replacement therapy that delivers a working SMN gene to treat spinal muscular atrophy (SMA), a rare genetic disease affecting motor nerve cells. The treatment is designed for infants and children with SMA to help restore survival motor neuron protein production.

1 investor

zPREDICTA manufactures three-dimensional tissue culture models derived from patient samples that recreate human organ microenvironments for drug testing. Pharmaceutical companies and researchers use the models to evaluate cancer drug candidates and predict clinical efficacy before human trials.

1 investor

Zura Bio is a clinical-stage biotechnology company developing antibody therapies for autoimmune diseases using a dual antagonism strategy that targets multiple immune pathways simultaneously. Its pipeline includes in-licensed assets such as tibulizumab, crebankitug, and torudokimab, advancing through Phase 2 trials for conditions like systemic sclerosis and hidradenitis suppurativa.

1 investor

1 investor

Zylem Biosciences develops Metabolic Redox Modulators (MRMs), a patented platform of drug candidates targeting the SR-B1 receptor to treat cancer, cardiovascular disease, and other age-related conditions. The company leverages fifteen years of research from Northwestern University to create therapeutics that induce metabolic dysfunction in disease cells while sparing healthy cells.

1 investor

Zyme Communications provides PR and marketing services to life science companies across Europe and the USA, helping them build visibility with investors, commercial partners, and customers through specialized communications and media outreach.

1 investor

Zymofix develops microbial production using solid-state fermentation, cultivating microorganisms on solid substrates in scalable bioreactors. The company combines microbiology, process development, and formulation expertise to support production at larger volumes.

1 investor

Zywie is a therapeutics company developing small-molecule treatments, including pharmacological chaperones and deuterated and halogenated forms of Ambroxol, for metabolic and neurodegenerative Lysosomal Storage Diseases (LSDs). Its drug-development approach targets protein misfolding and impaired protein trafficking within cells.

1 investor

ZZ Biotech develops 3K3A-APC, a genetically engineered variant of human activated protein C (a serine protease) optimized for therapeutic use. The company has agreed in principle to license its 3K3A-APC dermatology program to Dermatherix for wound therapy applications.

1 investor

GREEN VET is a pet healthcare diagnostics and services company providing diagnostic testing, health screening, and veterinary care solutions to veterinarians in South Korea. Founded as part of the GC group, it operates as a total animal healthcare provider serving the domestic veterinary industry.

1 investor

NeoCannBio is a technology spin-off from KIST developing cannabinoid-based pharmaceuticals and producing hemp-derived cannabinoid drug ingredients, including high-purity CBD via microwave processing and GMP production. The company builds a broad cannabinoid library and develops new drugs for patients with rare and intractable diseases in Korea.

1 investor

Novelty Nobility develops antibody and protein therapeutics for clinical applications. The company's leadership team brings expertise in immunization, affinity maturation, and biopharmaceutical development across therapeutic areas including ophthalmology.

1 investor

Novorex is a drug discovery company that combines AI, fragment-based drug discovery (FBDD), and biophysical validation (SPR, NMR, X-ray crystallography, and wet-lab assays) to develop novel small-molecule therapeutics. It operates in-house CNS and inflammation pipelines with R&D labs in Pangyo, Central, and Jeongeup.

1 investor

NeuroVenti is a biotech company developing neuroprotective and therapeutic agents for neuronal and central nervous system disorders, including a drug candidate (NV01-A02) for autism spectrum disorder currently in domestic Phase 2 clinical trials. It also offers preclinical CDRO services such as candidate discovery, preclinical research consulting, and efficacy and safety evaluation.

1 investor

Deep Bio is a medical AI company that develops cancer diagnostic software using deep learning technology. The company conducts clinical trials on its medical devices and plans to commercialize products in domestic and international biotech markets.

1 investor

Renhaim is a biotechnology company developing advanced RNA-based pharmaceuticals, including cancer therapeutics, preventive vaccines, and gene/cell therapies for unmet medical needs.

1 investor

LigaChemBio is a biotechnology company focused on drug development, particularly in ADC (antibody-drug conjugate) and small molecule therapeutics. The company develops and partners on therapeutic pipelines for pharmaceutical applications.

1 investor

Biosolution develops cell-based pharmaceuticals, human tissue models, natural cosmetic ingredients, and human-derived materials for pharmaceutical and cosmetic applications. The company provides contract research services including alternative testing methods, cosmetic ingredient development, and cosmetic consulting.

1 investor

Vitrosys is a South Korean company focused on plant tissue and cell culture, bioreactors, and extraction/purification research, including mass propagation of sterile seedlings and breeding of rare and endangered species. It also develops smart farm systems using ICT and AI, and produces functional health supplement products (sticks, pouches, ampoules, drinks, and concentrates) derived from cultured wild ginseng roots.

1 investor

Cellebrain is a biotech company developing stem cell-based gene therapies for intractable diseases that currently lack pharmacological treatments. It focuses on gene-cell therapies aimed at improving the quality of life for patients with cancer and chronic diseases.

1 investor

Develops a stem-cell-based protein production platform that grows Korean Hanwoo beef stem cells using seaweed-derived scaffolds and microalgae culture medium without fetal bovine serum. Its cultured cells are used for cultivated meat food products, while skin cells become leather and cells/medium feed into biomaterials and cosmetics, operated from a GMP Class D facility in Korea's Gyeongbuk cell-cultured food regulatory free zone.

1 investor

Avixgen develops therapeutic treatments for ophthalmological diseases such as macular degeneration and dry eye, inflammatory conditions including atopic dermatitis, and an in-house drug delivery platform called ACP technology.

1 investor

FNCT Biotech is a biotech company based in South Korea. The page provides limited information about the company's specific products or services beyond its investment and program participation history.

1 investor